Alpha/Beta T-cell Depleted Blood-forming Stem Cell Transplant From Related

Status Not yet recruiting

Clinical Trial Summary

This single institution, phase I clinical trial will determine the safety and feasibility of employing T-cell receptor (TCR) αβ+ and CD19+ (Cluster of Differentiation ) depleted hematopoietic stem cell transplantation (HSCT) using peripheral blood stem cells (PBMC) from closely matched unrelated donors or haploidentical donors to treat non-malignant hematologic diseases in children and young adults. Allogeneic hematopoietic stem cell transplantation has become a curative option for children and adolescents with a variety of otherwise fatal conditions. To reduce the incidence and severity of graft-versus-host disease (GVHD) associated with allogeneic hematopoietic stem cell transplantation, donor grafts are depleted of T cells, either using CD34+ selection or CD3+/CD19+ depletion of grafts. However, these selection processes also deplete the graft of protective cell subsets, such as γδ T cells, natural killer(NK) cells, monocytes and dendritic cells, which play important roles in the immune response to infectious agents. Moreover, the presence of NK cells and γδ T in donor grafts is associated with more rapid immune reconstitution after HSCT transplantation. In order to retain these protective immune cell subsets, this trial will use a novel, highly selective graft engineering process using the Miltenyi CliniMACS system that selectively depletes αβ-T cells and B cells which are responsible for GVHD and Epstein Barr Virus (EBV)-related post-transplantation lymphoproliferative disorder, respectively. Prior to transplantation, patients will be treated with a conditioning regimen, specific for the original disorder. The primary objective of this study is evaluation of the safety and feasibility of HSCT using TCRαβ+/CD19+ depleted hematopoietic stem cells to treat non-malignant hematologic diseases. This will be assessed by evaluating the incidence of graft failure, grade III-IV acute GVHD and chronic GVHD and TRM. Secondary objectives include the evaluation of immune reconstitution and incidence of post-transplant infections, adverse events, serious adverse events, overall and disease-free survival and the efficiency of graft processing by the CliniMACS System.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04806347
Study type	Interventional
Source	University of Wisconsin, Madison
Contact	Jenny Weiland
Phone	608-890-8070
Email	PedsHemOncResearch@lists.wisc.edu
Status	Not yet recruiting
Phase	Phase 1
Start date	August 2024
Completion date	May 2029

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT00106015` - Diamond Blackfan Anemia Registry (DBAR)
Completed	`NCT00059293` - Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG
Completed	`NCT00023530` - Blood and Marrow Transplant Clinical Research Network	N/A
Not yet recruiting	`NCT05983536` - The Evaluation of Anti-interference Ability and Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)
Recruiting	`NCT03548766` - Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping	Phase 3
Completed	`NCT00007371` - Hepatitis C in Clinically Discordant Hemophilic Siblings	N/A
Completed	`NCT00005682` - Aplastic Anemia Epidemiology: Incidence and Case-control	N/A
Completed	`NCT00000587` - Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection	Phase 2
Completed	`NCT00005305` - Hepatitis Delta Infections in Hemophiliacs	N/A
Completed	`NCT00005304` - Delta Hepatitis and Liver Disease in Hemophiliacs
Completed	`NCT00005277` - Cooperative Study of The Clinical Course of Sickle Cell Disease	N/A
Completed	`NCT00035763` - Pain in Sickle Cell Epidemiologic Study	N/A
Completed	`NCT00005300` - Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease	N/A
Recruiting	`NCT04600609` - Examining the Experiences of Children With Blood Disorders
Not yet recruiting	`NCT03881917` - Cystatin c and Beta 2 Microglobulin in Thalassemic Children.
Completed	`NCT00005556` - Retention of Bone Marrow Donors in a National Registry	N/A
Completed	`NCT00000597` - Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders	Phase 3
Completed	`NCT03586180` - Medical Clowning: Needs Assessment and Implication for Hospitalized Children With Cancer/Blood Disease
Recruiting	`NCT03848962` - Collection and Distribution of Biospecimens for Novel Research Uses
Terminated	`NCT00486720` - Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Alpha/Beta T-cell Depleted Blood-forming Stem Cell Transplant From Related or Unrelated Donors for Blood Diseases in Children and Young Adults

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms